Dianthus Therapeutics Inc DNTH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
-
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
-
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Dianthus Therapeutics to Participate in Three Investor Conferences During September
-
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 2026 Financial Results
-
Dianthus Therapeutics Announces DNTH312, a First-In-Class, Next-Generation Bifunctional Fusion Protein Combining Claseprubart and TACI, for Severe Autoimmune Diseases
-
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Trading Information
- Previous Close Price
- $78.75
- Day Range
- $77.26–80.74
- 52-Week Range
- $32.22–117.88
- Bid/Ask
- $58.56 / $97.75
- Shares Outstanding
- 55.93M
- Market Cap
- $4.37B
- Volume/Avg
- 1M / 828,004
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,917.27
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 92
- Website
- https://www.dianthustx.com
Valuation
|
Metric
|
DNTH
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.65 |
Price/Sales | 1,917.27 |
Price/Cash Flow | — |
Price/Earnings
DNTH
Financial Strength
|
Metric
|
DNTH
|
|---|---|
Quick Ratio | 25.79 |
Current Ratio | 26.10 |
Interest Coverage | — |
Quick Ratio
DNTH
Profitability
|
Metric
|
DNTH
|
|---|---|
Return on Assets (Normalized) | −20.32% |
Return on Equity (Normalized) | −21.29% |
Return on Invested Capital (Normalized) | −24.84% |
Return on Assets
DNTH
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>cj^Gy | LOCK|HRpF | $133B | |||
| Moderna Inc
MRNA
| LOCK|$Z?!<W> | LOCK|GV | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$RPR<<^ | LOCK|btw!< | $83B | |||
| argenx SE ADR
ARGX
| LOCK|LH&Tc% | LOCK|C^T | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&z$g!t | LOCK|P%^ | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|fz!zzgC | LOCK|XPz% | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#&C<@rf | LOCK|R&J%! | $28B | |||
| Incyte Corp
INCY
| LOCK|^k<hPg | LOCK|d^R | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Mm^wfZ^ | LOCK|s^X | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$sGZ#>k | LOCK|@g$ | $14B |
United States